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Abstract
Interleukin 17 (IL-17)-producing TH17 cells are often present at the sites of tissue inflammation in
autoimmune diseases, which has lead to the conclusion that TH17 are main drivers of autoimmune
tissue injury. However, not all TH17 cells are pathogenic, in fact TH17 generated with TGF-β1 and
IL-6 produce IL-17 but do not readily induce autoimmune disease without further exposure to
IL-23. Here we show that TGF-β3, produced by developing TH17 cells, is dependent on IL-23,
which together with IL-6 induces highly pathogenic TH17 cells. Moreover, TGF-β3-induced TH17
cells are functionally and molecularly distinct from TGF-β1-induced TH17 cells and possess a
molecular signature that defines pathogenic effector TH17 cells in autoimmune disease.
Upon antigenic stimulation, naïve CD4+ T cells activate, expand and differentiate into
different effector phenotypes 1. T helper type 1 (TH1) cells, induced by the transcription
factor Tbx21 (T-bet) produce interferon-γ (IFN-γ), interleukin 2 (IL-2) and lymphotoxin
(LT) and were shown to be crucial for clearing intracellular pathogens 2, 3. In contrast, TH2
cells that are generated by the transcription factor GATA-3 produce IL-4, IL-5, IL-13 and
were shown to be critical for clearing extracellular pathogens 4, 5. An exaggerated TH1
response against self-antigens was implicated in inducing autoimmune diseases 6. However,
the loss of IFN-γ or IFN-γ receptor (IFN-γR) did not induce resistance to developing
autoimmune diseases 7, 8, in fact, mice deficient for these proteins were found to be highly
susceptible to autoimmununity 7, 8. Paradoxically, loss of the TH1-specific transcription
factor, T-bet, made these mice resistant to multiple autoimmune diseases including
experimental autoimmune encephalomyelitis (EAE), an animal model of the human disease
multiple sclerosis (MS) 9. This raised the issue of what is the role of T-bet in inducing EAE,
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tbecause the production of IFN-γ is not required for conferring encephalitogenicity to
effector TH1 cells.
TH17 cells, which have been characterized as an additional effector T cell subset that
produce IL-17A, IL-17F, IL-21 and IL-22, have been suggested to be the critical driver of
autoimmune tissue inflammation 10–14. TH17 cells were observed to be expressed at the sites
of tissue inflammation and have been associated with the induction of many human
autoimmune diseases including psoriasis, inflammatory bowel disease (IBD), rheumatoid
arthritis (RA), type 1 diabetes and MS 14. TH17 cells are differentiated by a combination of
TGF-β1, IL-6 and IL-1 cytokines, which induces RORγt, a transcription factor required for
their generation 10, 12, 13, 15. Whereas TGF-β1 plus IL-6 can induce TH17 cells, exposure to
another cytokine, IL-23, was shown to be crucial for their stabilization and for their ability
to induce autoimmune tissue inflammation in EAE16–18. IL-23R polymorphism has been
genetically linked to many human autoimmune diseases including psoriasis, IBD and
ankylosis spondylitis 19, 20. Exposure to IL-23 was shown to reduce the levels of the anti-
inflammatory cytokine IL-10 in developing TH17 cells, thus making these cells
pathogenic 21. However, this also raised the question whether there are cytokines or effector
molecules dependent on IL-23 that make them pathogenic to induce inflammation in
autoimmune disease.
Although TH17 cells were thought to be pathogenic11, 22, accumulating data indicates the
existence of non-pathogenic IL-17 producing TH17 cells 23, 24. It remains unclear whether
there is a differential requirement for their induction and what makes a TH17 cell pathogenic
or nonpathogenic. Recent studies have shown that GM-CSF (CSF-2), which is produced by
TH17 and transactivated by RORγt, is required for conferring pathogenicity to TH17
cells 25, 26. Indeed, GM-CSF-deficient mice are highly resistant to the induction of
EAE 25, 27. However, it remains unclear why T-bet−/− mice are resistant to the induction of
EAE and other autoimmune diseases, suggesting that T-bet must have additional roles in the
induction of pathogenic TH17 cells in EAE 24. T-bet is expressed in TH17 cells24, but
whether it plays a role in inducing pathogenic function of TH17 cells has not been addressed.
In this study we have identified an endogenous cytokine, TGF-β3, which is specifically
produced by developing TH17 cells in an IL-23 dependent manner that is important for
driving pathogenic TH17 phenotype. Whereas TGF-β1 plus IL-6 differentiate naïve T cells
into TH17 cells, these T cells are not pathogenic unless they are further exposed to IL-23.
We now show that IL-23 is critical for enhancing expression and/or maintaining the
endogenous levels of TGF-β3 in developing TH17 cells. In fact, differentiation of TH17 cells
in the presence of TGF-β3 and IL-6 makes TH17 cells pathogenic without any need for
further exposure to IL-23. Using these subsets of pathogenic and non-pathogenic TH17 cells,
we have identified a molecular signature associated with pathogenic TH17 cells.
Results
TGF-β3 induction in TH17 cells
TGF-β1 and IL-6 are required for differentiation of TH17 cells10, 12, 13. However, TH17 cells
induced by TGF-β1 plus IL-6 are not pathogenic, unless they are further exposed to IL-23
for a prolonged period of time 21, 22. In the EAE model, only adoptive transfer of myelin
oligodendrocyte peptide (amino acid 35–55 (MOG35–55)) specific TCR transgenic CD4+ T
cells (2D2) that were differentiated with TGF-β1-IL-6-IL-23 results in the induction of
severe disease while T cells differentiated with TGF-β1-IL-6 develop mild to no disease,
with majority of the recipient mice recovering rapidly within 24 days after the onset of
clinical disease (Fig. 1a and Table 1). To investigate the role of IL-23 in the induction of
pathogenic TH17 cells, we undertook detailed temporal microarray analysis that revealed a
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tstrong induction of TGF-β3 in developing TH17 cells exposed to TGF-β1-IL-6-IL-23
(Supplementary Fig. 1a), which was dependent on IL-23R signaling (Supplementary Fig.
1b). Quantitative RT-PCR confirmed the induction of TGF-β3 in TH17 cells (Fig. 1b). Naïve
T cells activated in the presence of TGF-β1-IL-6 or TGF-β1-IL-6-IL-23 both expressed
TGF-β3. However, IL-23R-deficient CD4+ T cells under TGF-β1-IL-6-IL-23 condition
failed to enhance or maintain TGF-β3 expression (Fig. 1c). IL-23 was not required for the
initial induction of TGF-β3, which was induced by IL-6 (Supplementary Fig. 1c), but the
presence of IL-23R was required for maintaining TGF-β3 expression (Fig. 1c).
It remains unknown if cells of the hematopoietic origin can produce TGF-β3. To investigate
TGF-β3 protein expression, we generated TGF-β3-YFP fate reporter mice (TGF-
β3CreR26ReYFP) by crossing mice that express the Cre recombinase in the TGF-β3 locus
(TGF-β3Cre) 28 with reporter mice expressing eYFP under the Rosa26 promoter. Analysis of
lymphoid tissue from the TGF-β3CreR26ReYFP mice revealed that TGF-β3 was produced in
CD4+, CD8+, γσ T and B cells (Fig. 1d), but not by cells of the myeloid lineage (CD11b+
and/or CD11c+ cells) (data not shown). This observation suggested that TGF-β3 is
endogenously produced by the hematopoietic cells. To address whether in vivo
differentiating TH17 cells induces TGF-β3 expression and determine whether TGF-β3
expression is enhanced in response to IL-23, we immunized TGF-β3CreR26ReYFP mice with
MOG35–55 emulsified in complete Freund’s adjuvant (CFA) and reactivated T cells in the
presence of IL-23 in a recall assay. A small percentage of IL-17 expressing and non-
expressing T cells produced TGF-β3 upon activation, but exposure to IL-23 largely
restricted TGF-β3 expression to IL-17-producing TH17 cells. This was true in both CD4+
(Fig. 1e) and non-CD4+ T cell (Supplementary Fig. 1c) subsets. We also addressed whether
TGF-β3 is co-produced by IFN-γ producing TH1 cells, which are also induced by
immunization with MOG35–55+CFA. IFN-γ producing T cells did not co-express TGF-β3
(Fig. 1e). This was true for non-CD4+ T cells as well (Supplementary Fig. 1d), suggesting
that TGF-β3 may be mostly expressed by IL-17 producing cells. In addition, deletion of
TGF-β3+ cells in vivo in TGF-β3CreR26RDTR mice (TGF-β3Cre mice crossed to mice
expressing the diphtheria toxin receptor (DTR) under the Rosa26 promoter) that were
immunized with MOG35–55+CFA resulted in selective ablation of IL-17+ cells, while IFNγ+
T cell numbers remained unchanged upon diphtheria toxin (DT) treatment (Fig. 1f). CD4+ T
cells derived from TGF-β3fl/fl mice in which TGF-β3 was deleted through the retroviral
expression of a GFP-Cre, but not control retrovirus treated T cells, showed severely
compromised IL-17 production in TH17 differentiation conditions (Fig. 1g). These findings
reveal that TH17 cells produce TGF-β3 endogenously and that exposure to IL-23 largely
restricted the expression of TGF-β3 to IL-17-producing cells.
TGF-β3-induced TH17 cells are highly pathogenic
To determine whether TGF-β3 can induce TH17 cells, we polarized naive CD4+ T cells into
TH17 cells with either TGF-β1-IL-6 or TGF-β3-IL-6 and compared the expression of IL-17
and other TH17 associated molecules. TGF-β3-IL-6-induced TH17 cells expressed
comparable amount of IL-17 as TGF-β-IL-6-induced TH17 cells (Fig. 2a,b). Similar to TGF-
β1-induced TH17 cells, TGF-β3-induced TH17 cells expressed Rorc, Il17a, Il17f, but no
Ifnγ mRNA (Fig. 2c). However, TGF-β3-induced TH17 cells had significantly higher
expression of Il23r and Il22 when compared to TGF-β1-induced TH17 cells (Fig. 2d). The
higher expression of IL-23R protein in TGF-β3-induced TH17 cells was confirmed in
IL-23R-GFP reporter mice16 (Fig. 2e).
Because IL-23 induces TH17 cells to become pathogenic and IL-23 can enhance and
maintain expression of TGF-β3, we investigated the pathogenicity of TGF-β3-IL-6-induced
TH17 cells. TH17 cells generated from naive 2D2 TCR transgenic (Tg) T cells with either
TGF-β1-IL-6 or TGF-β3-IL-6 were transferred into naive recipients and development of
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tEAE was monitored. In contrast to TGF-β1-IL-6-induced TH17 cells, which transferred a
very mild disease (Fig. 2f and Table 1), TGF-β3-IL-6-induced TH17 cells transferred EAE
with a high disease incidence, severity and mortality (Fig. 2f and Table 1). Histo-
pathological quantification of CNS lesions showed significantly more parenchymal and
meningeal inflammatory lesions in the TGF-β3-IL-6 groups in comparison to the recipients
of TGF-β1-IL-6 TH17 cells (Fig. 2g), suggesting that TGF-β3-induced TH17 cells are highly
pathogenic.
We next addressed how TGF-β1 and TGF-β3 can induce such a difference in the
pathogenicity of TH17 cells, considering they both have been suggested to signal through a
common TGF-βRII subunit29, 30. Mice expressing a dominant negative (DN) for of TGF-
βRII (here called TGF-βRII DN mice) were previously shown to be to have reduced
generation of TH17 cells and to be protected from EAE 13. We tested whether TGF-β3,
similar to TGF-β1, requires TGF-βRII for the development of TH17 cells. To address this,
we generated TGF-βRII DN × IL-17A-eGFP reporter mice and CD4+ T cells from these
mice were differentiated with either TGF-β1-IL-6 or TGF-β3-IL-6 conditions. Both TGF-β1
and TGF-β3 were unable to induce the differentiation of TH17 cells in TGF-βRII DN T cells
(Supplementary Fig. 2a), suggesting that both TGF-β1 and TGF-β3 signal through TGF-
βRII for TH17 differentiation (Fig. 2d–f).
To test the possibility that TGF-βRII transmits different downstream signals upon ligation
with TGF-β1 or TGF-β3, we performed a comprehensive TGF-β signaling PCR array
analysis for TH17 cells generated with either TGF-β1 or TGF-β3. This array allowed us to
determine the expression of approximately 90 known signaling molecules downstream of
TGF-βRII and showed that TGF-β1 and TGF-β3 induced different expression profiles of
target genes downstream of TGF-βRII engagement (Supplementary Fig. 2b). In particular,
TGF-β3-IL-6-differentiated TH17 cells induced higher expression of Smad1 and Smad5 and
lower expression of Smad3 when compared to TGF-β1/IL-6-induced TH17 cells (Fig. 2h).
Consistent with the PCR array data, TGF-β3 induced less Smad2 and Smad3
phosphorylation than TGF-β1, while phosphorylation of Smad 1 and Smad5 was greatly
enhanced (Fig. 2i, Supplementary Fig. 2c). Taken together, these data indicate that TGF-β3-
IL-6-induced TH17 cells were functionally distinct from TGF-β1-IL-6-induced TH17 cells,
and that the difference in the functionality of TH17 cells was supported by the differential
signaling induced by TGF-β1 and TGF-β3 through TGF-βRII.
TGF-β3-IL-6 and IL-1β-IL-6-IL-23 TH17 cells are comparable
TGF-β-independent TH17 cells, which are induced by a combination of IL-1β/IL-6/IL-23
and are highly pathogenic compared to TGF-β1/IL-6-derived TH17 cells, have been recently
described 31. We therefore compared the ability of TGF-β3-IL-6 and IL-1β-IL-6-IL-23
pathogenic TH17 cell populations to transfer EAE. TH17 cells differentiated with either
TGF-β3-IL-6 or IL-1β-IL-6-IL-23 showed comparable IL-17 protein (Fig. 3a) and IL-23R
mRNA (Fig. 3b) expression. Because the IL-23-IL-23R axis is essential for the development
of pathogenic TH17 cells 16–18, we tested whether the high expression of IL-23R contributed
to the pathogenicity of TGF-β3-IL-6-or IL-1β-IL-6-IL-23-differentiated TH17 cells.
Adoptively transferred 2D2 T cells differentiated into TH17 cells with TGF-β3-IL-6 or
IL-1β-IL-6-IL-23 into wild-type recipients transferred EAE with similar severity and
incidence. Transfer of IL-23R-deficient 2D2 T cells failed to induce EAE in both TGF-β3-
IL-6 and IL-1β-IL-6-IL-23 differentiating condition (Fig. 3c and Table 1). This indicates
that IL-23-IL-23R pathway is absolutely critical for the development of pathogenic TH17
cells induced by either TGF-β3-IL-6 or IL-1β-IL-6-IL-23.
Further analysis of CNS-infiltrating T cells showed that TGF-β3-IL-6-induced TH17 cells
maintained higher IL-17 expression (~25%) and did not produce as much IFN-γ as IL-1β-
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tIL-6-IL-23 induced TH17 cells (~15%) (data not shown). To address if TGF-β3 is involved
in EAE induction following active immunization, we immunized mice with
MOG35–55+CFA, which is known to induce EAE by generating MOG35–55-specific TH1 and
TH17 cells. CD4+ T cells infiltrating the CNS in MOG35–55+CFA immunized mice showed
a significantly higher expression of TGF-β3 in mice that developed the disease (score 2–3)
compared to mice with no clinical signs of disease (score 0), even though there was
infiltration of CD4+ T cells in the CNS of these mice (Fig. 3d). Local blockade of TGF-βs
by adding neutralizing anti-TGF-β1,2,3 antibody in the immunizing emulsion was shown to
prevent the development of TH17 cells and EAE 32, suggesting an in vivo role of TGF-β in
the development of TH17 cells and the disease. However, the study did not reveal which
TGF-β was required for the development TH17 cell, since anti-TGF-β1,2,3 neutralizes all
three forms of TGF-β proteins. We therefore tested whether neutralizing TGF-β3 locally
affects the development of EAE. The inclusion of anti-TGF-β3 antibody into the
MOG35–55+CFA emulsion at the time of induction significantly inhibited the development
of EAE (Fig. 3e and Table 1), suggesting that endogenous TGF-β3 contributes to the
induction of EAE. Taken together, these data indicate that the pathogenic TH17 cells
induced by TGF-β3 have a pathogenic and functional phenotype comparable to that of
recently described IL-1β/IL-6/IL-23 TH17 cells.
The transcriptional signature of pathogenic TH17 cells
To characterize the molecular state associated with the different functionally of TGF-β1 and
TGF-β3-induced TH17 cells, we measured the mRNA profiles of in vitro differentiated
TH17 cells using whole genome microarrays. We compared the gene expression profiles of
naïve CD4+ T cells differentiated into TH17 cell under six different polarizing conditions:
IL-β1-IL-6, IL-β1-IL-6-IL-23, TGF-β1-IL-6, TGF-β1-IL-6-IL-23, TGF-β3-IL-6 and TGF-
β3-IL-6-IL-23. Activated TH0 cells with the same TCR specificity that produce IL-4 and
IFN-γ were used as controls. We found 434 genes that were differentially expressed, up-
regulated or down-regulated at least 2 fold in TH17 cells in comparison to control TH0 cells
(Fig. 4a). Across these 434 genes, the transcriptional profile of TH17 cells differentiated
with IL-1β-IL-6 or IL-1β-IL-6-IL-23 was similar to that of TH17 cells differentiated with
TGF-β3-IL-6 or TGF-β3-IL-6-IL-23, whereas the TH17 cells differentiated with TGF-β1-
IL-6 or TGF-β1-IL-6-IL-23 had a distinct transcriptional profile (Fig. 4a). Direct
comparison of the transcriptional profiles of TH17 cells differentiated with TGF-β1-IL-6 or
TGF-β3-IL-6, as these two different differentiation conditions led to significant differences
in the pathogenicity of TH17 cells, revealed 233 genes that were differentially expressed
(Supplementary Table 1). Based on their biological function, we selected a representative
subset of 23 genes (Fig. 4b) and validated their differential expression by qPCR (Fig. 4c).
TGF-β3-IL-6-induced TH17 cells were characterized by the higher expression of transcripts
that could be broadly divided into 3 different modules: cytokines/chemokines (Cxcl3, Ccl4,
Ccl5, Ccl3, Csf2, Il3, Il22 and Casp1, which is involved in the generation of mature IL-1β),
transcription factors (Tbx21 and Stat4), and effector molecules (Gzmb, Lag3 and Lglas3
(encoding Galectin-3)). In addition, TGF-β3-IL-6-induced TH17 cells had downregulated,
while TGF-β1-IL-6-induced TH17 cells had upregulated, molecules that are broadly
associated with immune regulation (regulatory module), including Il10 and molecules
involved in the regulation of IL-10 production (Ahr and Maf), Il9, Il1rn and the transcription
factor Ikzf3 (Aiolos) (Fig. 4c).
Based on this molecular signature, we compared the profiles of each of these TH17
populations (Fig. 4d). Principal component analysis (PCA) revealed 3 groups: group I
includes TGF-β1-IL-6-induced TH17 cells, regardless of whether they were exposed to
IL-23. These cells show a mild or no pathogenic phenotype in vivo (Fig. 1a) and express
little or no IL-23R (Fig. 2d,e). Group II includes TH17 cells induced with TGF-β3-IL-6 and
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tIL-1β-IL-6. These cells are highly pathogenic in vivo (Figs. 2f) and express high levels of
IL-23R (Fig. 2d,e). Group III includes TH17 cells induced with TGF-β3/IL-6/IL-23 and
IL-1β/IL-6/IL-23, which also expressed high levels of IL-23R (Fig. 3b). Similar results were
obtained when PCA was performed based on the expression of all 233 genes that are
differentially expressed between TGF-β1-IL-6-induced and TGF-β3-IL-6-induced TH17
cells (Fig. 4e). These results show that TGF-β3-IL-6-induced TH17 cells are closely related
to IL-1β-IL-6-induced TH17 cells, and differ from TGF-β1-IL-6-induced by TH17 cells. The
23-gene transcriptional signature of TH17 cells defined here provides a means to identify
key molecules involved in pathogenicity of TH17 cells.
TGF-β3 overcomes lack of pathogenicity in Tbx21−/− TH17 cells
Our microarray analysis showed that TGF-β3-IL-6-induced TH17 cell expressed relatively
higher level of the transcription factor Tbx21 (T-bet) (Fig. 4b). Because exposure of TH17
cells to IL-23 was shown to induce the expression of T-bet 33, we generated TGF-β1-IL-6-
IL-23-induced TH17 cells from 2D2 Tbx21−/− and wild type T cells. Tbx21−/− TH17 cells
induced higher expression of IL-17A as compared to wild-type TH17 cells (Fig. 5a),
however 2D2 Tbx21−/−TH17 failed to transfer EAE, whereas wild-type 2D2 TH17 cells
induced disease with high incidence and severity (Fig. 5b). This data indicates that T-bet
plays a key role in inducing pathogenic functions of TH17 cells, and this is independent on
IL-17 production. Because TGF-β3 is required for the induction of pathogenic signatures in
TH17 cells, we tested whether the inability of T-bet-deficient T cells to induce disease was
due to a decrease in TGF-β3 expression. In fact, TGF-β3 expression was decreased in T-bet-
deficient TH17 cells (Fig. 5c). Conversely, retroviral over-expression of T-bet enhanced the
expression of TGF-β3 (Fig. 5d). We next tested whether compensating for TGF-β3 in T-bet-
deficient TH17 cells could induce EAE in an adoptive transfer system. Polarization of 2D2
Tbx21−/− CD4+ T cells in the presence of TGF-β3-IL-6, but not TGF-β1-IL-6-IL-23 or
TGF-β1-IL-6, overcame the requirement of T-bet and were encephalitogenic (Fig. 5e and
Table 1). Histological analysis showed that adoptively transferred TGF-β3-IL-6-induced
2D2 Tbx21−/− cells produced CNS lesions in the meninges and the parenchyma, while TGF-
β1-IL-6-induced 2D2 Tbx21−/− cells produced no detectable lesions after transfer (Fig. 5f).
T-bet-deficient T cells produced relatively higher amounts of IL-17 when differentiated with
TGF-β1-IL-6-IL-23 or TGF-β3-IL-6 (Fig. 5g). Previous reports have suggested a
requirement for IFN-γ-producing cells to breach the blood brain barrier in order to allow
entry of IL-17 producing cells into the CNS 34. Analysis of peripheral or CNS isolated CD4+
T cells at the peak of disease revealed that TGF-β3-IL-6-induced 2D2 cells, but not 2D2
Tbx21−/− cells, expressed IFN-γ. This suggests that independent of IFN-γ production, TGF-
β3-IL-6-induced 2D2 Tbx21−/− TH17 cells were pathogenic in vivo (Supplementary Fig. 3).
These observations suggest that T-bet is part of the pathogenic TH17 signature and may
regulate the endogenous expression of TGF-β3. Loss of pathogenicity in T-bet–deficient
TH17 cells can be overcome by exogenous TGF-β3 and IL-6. It remains unclear whether T-
bet is directly or indirectly required for the induction and/or maintenance of TGF-β3.
Discussion
Although TH17 cells have been associated with induction of autoimmunity, emerging data
suggests that not all TH17 cell are pathogenic and exposure to IL-23 is crucial for their
ability to induce autoimmunity 16–18, 22. In this paper we show that TGF-β3 endogenously
produced by developing TH17 cells plays a critical role in inducing pathogenic TH17 cells
and T-bet a transcription factor normally associated with Th1 development is critical for the
generation of pathogenic TH17 cells.
While IFNγ−/− and IFNγR−/− mice are highly susceptible to developing EAE 7, 8 mice
lacking T-bet are protected from almost all autoimmune disease 9, 24. Our data begins to
Lee et al. Page 6
Nat Immunol. Author manuscript; available in PMC 2013 April 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
taddress this paradox by showing that T-bet is part of the pathogenic signature expressed by a
subset of TH17 cells. Although it remains unclear how T-bet confers encephalitogenic
potential of TH17 cells, we show that in the absence of T-bet, TH17 cells are not able to
induce endogenous TGF-β3. Whether T-bet is directly transactivating TGF-β3 or is
indirectly modulating other receptors/factors in TH17 cells is not clear at this stage. IL-23
signaling was shown to induce T-bet expression in TH17 cells and T-bet has been suggested
to induce IL-23R expression35, suggesting a feed-forward loop between IL-23R-signaling
and T-bet expression. Because T-bet expression in TH17 cells, it has been postulated that
TH17 cells might produce IFN-γ and therefore, IL-17-IFN-γ double producers are the main
pathogenic T cells that induce autoimmune disease. Our data suggests that the requirement
for T-bet expression in pathogenic TH17 cells is independent of IFN-γ production, because
IFN-γ-deficient TH17 cells induced with TGF-β3/IL-6 were still capable of inducing EAE
(data not shown). One possible reason why we observe T-bet expression in TGF-β3/IL-6
induced TH17 cells is that, unlike TGF-β1, which suppresses T-bet 36 and IL-23R37, TGF-
β3 promotes expression of these molecules, promoting the stability and pathogenicity of
TH17 cells.
In addition to T-bet, several other factors were associated with the pathogenic signature of
TH17, including GM-CSF, IL-23R and IL-7R. GM-CSF (csf2), which is transactivated by
RORγt, was recently described as the key cytokine involved in the pathogenicity TH17
cells 25, 26 and our transcriptional analysis independently identified GM-CSF as a
component of pathogenic TH17 cells. Indeed, GM-CSF-deficient mice are highly resistant to
EAE and GM-CSF-deficient TH17 cells are incapable of transferring EAE 25, 26. This is
consistent with our data that pathogenic TH17 cells induced by TGF-β3/IL-6 express GM-
CSF. However, it remains to be determined whether TGF-β3/IL-6-induced TH17 cells
require GM-CSF for encephalitogencity. Similarly, IL-23R is the key component of the
pathogenic TH17 signature. IL-23R-deficient mice are resistant to EAE and IL-23R-
deficient TH17 cells are unable to transfer EAE 16. The IL-7-IL-7R pathway has also been
implicated in development of TH17 cells and genetic data link IL-7R to susceptibility to
multiple sclerosis in patients 16, 38–41. However, the role of IL-7-IL-7R axis in the induction
of pathogenic potential of TGF-β3/IL-6-induced TH17 cells remains to be determined.
Whether IL-7 simply expands pathogenic TH17 cells or induces key molecules required for
pathogenicity of TH17 cells has not been addressed as of yet. A systematic analysis of each
of the molecules belonging to the pathogenic signature of TH17 cells will allow the
identification of key nodes in the development of pathogenic TH17 cells.
Acquisition of a pathogenic phenotype by TH17 cells is not only the consequence of the
upregulation of molecules that mediate pathology, but also of the downregulation of a
number of other genes. We found that genes generally associated with immune-regulation,
such as IL-10, Ahr and c-Maf, were significantly downregulated in pathogenic TH17 cells.
Ahr and c-Maf are induced by TGF-β1/IL-6 conditions42–44, and they work together to
transactivate IL-10 production 45. Failure to express these genes in TGF-β3/IL-6-induced
TH17 cells might explain why these cells become highly pathogenic. Conversely, it will be
interesting to determine whether TH17 cells induced by TGF-β1/IL-6 in the absence of Ahr,
cMaf or IL-10 expression can attain pathogenic functions. IL-10 has been previously
associated with non-pathogenic TH17 cells and exposure to IL-23 was shown to
downregulate IL-10 production and increase their encephalitogenicity 21, 22. In addition to
IL-10, nonpathogenic TH17 cells produced IL-1R antagonist (IL-1RN) and sIL-6R, both of
which would presumably inhibit IL-1 and IL-6 signaling and thus further suppress
differentiation of pathogenic TH17 cells. However, the relationship between IL-1R
antagonism and IL-10 production by TH17 cells remains unclear at this point. It remains to
be determined whether different subsets of TH17 cells, some that produces IL-17 and IL-10
and other that produces IL-17 and GM-CSF and express T-bet have evolved to clear
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tdifferent types of pathogens. Indeed, observations in human TH17 cells suggests that
IL-17+IL-10+ TH17 cells are specific for S. aureus infection whereas IL-17+IFN-γ+ TH17
cells are specific for C.albicans infection 46. Similarly, our study suggests a pathogenic
versus non-pathogenic subtypes of TH17 cells, and their development may be contingent on
the type of TGF-β present during the initial differentiation stage.
Existing data suggest that both pathogenic and non-pathogenic TH17 cells exist in the
repertoire. While the initial differentiation of IL-17-producing cells is not dependent on
exposure to IL-23, it is now clear that IL-23 is required for attaining full pathogenic
potential in TH17 cells by maintenance and stabilization of the TH17 phenotype, suppression
of IL-10 production, promotion of GM-CSF production and other effector molecules and
maintenance of TGF-β3 expression. The fact that enhancement and maintenance of TGF-β3
are dependent on IL-23 exposure is especially interesting given that TGF-β1/IL-6-
differentiated TH17 cells cannot transfer disease, yet when exposed to IL-23 they acquire
pathogenic potential and induce autoimmune disease. Thus, it is likely that the IL-23-
dependent TGF-β3 production in TGF-β1/IL-6-differentiated TH17 cells is required for the
induction of full pathogenic phenotype in TH17 cells to induce autoimmunity.
In summary, we report a critical role for TGF-β3 cell autonomously produced by TH17 cells
in inducing pathogenic TH17 cells. Whereas both TGF-β1 and TGF-β3 can induce TH17
cells, TGF-β3 induced TH17 cells differ from TGF-β1 induced TH17 cells in multiple ways.
TGF-β3 induced TH17 cells are not only pathogenic in inducing EAE but also very potent in
inducing colitis in the adoptive transfer model (data not shown), supporting a broader role of
TGF-β3 in inducing highly pathogenic and proinflammatory TH17 cells. Since TGF-β3
induces highly pathogenic TH17 in both EAE and colitis, TGF-β3 may provide a useful
target for regulating tissue inflammation in multiple autoimmune diseases.
Materials and Methods
Mice
C57BL/6 wild-type (wt), TGF-βRII DN mice were from the Jackson Laboratory. IL-17A-
GFP.KI mice were purchased from Biocytogen LLC (Worcester, MA). IL-23R-GFP.KI and
IL-23R−/− mice were generated as described 16. TGF-β3fl/fl mice were generously provided
by Dr. Ramireddy Bomireddy of University of Arizona. TGF-β3-YFP reporter mice were
generated by crossing TGF-β3Cre 28 mice with Rosa26YFP. TGF-β3-RosaDTR were
generated by crossing TGF-β3Cre 28 to Rosa26DTR mice. Wt, 2D2, 2D2xIL-23R−/−, 2D2xT-
bet−/−, T-bet−/−, IL-23R-GFP.KI, IL-17A-GFP.KI mice10 were housed and maintained in a
conventional pathogen-free facility at the Harvard Institute of Medicine in Boston, MA. All
experiments were performed in accordance to the guidelines outlined by the Harvard
Medical Area Standing Committee on Animals at the Harvard Medical School (Boston,
MA).
Cell sorting, flow cytometry, p-smad and intracellular cytokine staining (ICC)
Cells were sorted with anti-CD4-PerCP, anti-CD62L-APC, anti-CD44-PE antibodies (all
Biolegend, CA). Cells were stimulated with phorbol 12-myristate 13-aceate (PMA)
(50ngml−1, Sigma-aldrich, MO) and ionomycin (1µgml−1, Sigma-aldrich, MO) and a protein
transport inhibitor containing monensin (Goligistop) (BD Biosciences) for four hours prior
to detection with staining with antibodies. Surface markers were stained in PBS with 1%
FCS for 20 min in room temperature, then subsequently fixed in Cytoperm/Cytofix (BD
Biosciences), permeabilized with Perm/Wash Buffer (BD Biosciences) and stained with
cytokine antibodies (anti-IFN-γ-APC anti-IL-17A-alexa fluora 488 ab, all from Biolegend)
diluted in Perm/Wash buffer as described previously 10. For psmad signaling flow
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tcytometry, LN and SP cells from C57BL/6 wt mice were labeled with CD4 microbeads
(Miltenyi Biotec, MA) then purified via the Automacs (Miltenyi Biotec, MA). Cells were
stimulated in serum free media and serum starved overnight then subsequently cultured with
either TGF-β1 or TGF-β3 (2ng/ml) for 30 min. Cells were fixed with Cytoperm/Cytofix
(BD Biosciences), permeabilized with Perm/Wash Buffer (BD Biosciences), then stained
with psmad2&3, psmad1&5, and isotype control antibodies (all Cell Signaling, MA). Data
was collected using FACS Calibur or LSR II (Both BD Biosciences), then analyzed using
Flow Jo software (Treestar, OR) 16, 47.
Active and passive EAE induction and disease analysis
For active EAE induction, mice were immunized with 100µg MOG35–55 peptide
(MEVGWYRSPFSRVVHLYRNGK) in CFA injected subcutaneously, mice received
pertussis toxin (List Biological Laboratory, CA) via intraperitoneally (i.p.). For local
blockade of TGF-β3, 100ng/ml anti-TGF-β3 antibody (R&D, MN) was incorporated into
the emulsion, and mice received 200ng of pertussis toxin on day 0 and 2. For passive EAE
induction, cells were differentiated and adoptively transferred as previously described 16, 22.
Animals were monitored and scored daily for development of EAE according to the
following criteria: Animals were monitored daily for the development of classical and
atypical signs of EAE according to the following criteria: 0, no disease; 1, decreased tail
tone or mild balance defects; 2, hind limb weakness, partial paralysis or severe balance
defects that cause spontaneous falling over; 3, complete hind limb paralysis or very severe
balance defects that prevent walking; 4, front and hind limb paralysis or inability to move
body weight into a different position; 5, moribund state22.
Analysis of CNS infiltrating mononuclear cells
At the peak of disease, mice were sacrificed for analysis of CNS infiltrating cells. Mice were
perfused through the left ventrical of the heart with cold PBS. The brain and the spinal cord
were flushed out with PBS by hydrostatic pressure. CNS tissue with minced with a sharp
razor blade and digested with collagenase D (2.5mg/ml, Roche Diagnostics, IN) and DNaseI
(1mg/ml, Sigma, MO) at 37°C for 20 minutes. Mononuclear cells were isolated by passing
the tissue through a cells strainer (70um), followed by a percoll gradient (37% and 70%)
centrifugation. Mononuclear cells in the interphase was removed, washed and resuspended
in culture medium for analysis by intracellular cytokine staining.
In vitro T-cell differentiation
CD4+ T cells were purified from spleen and lymph nodes using anti-CD4 microbeads
(Miltenyi Biotech) then further sorted for naïve CD4+ CD62Lhi CD44low T cells. Sorted
cells were activated with plate bound anti-CD3 (2µg/ml) and anti-CD28 (2µg/ml) in the
presence of cytokines (rmIL-23: R&D Systems, all other cytokines: Miltenyi Biotec). Anti-
TGF-β3 (R&D Biosystems) were neutralized at 30µg/ml. For TH17 differentiation: 2ng/mL
rhTGF-β1 and rhTGF-β3 (Miltenyi Biotec), 25ng/mL rmIL-6 (Miltenyi Biotec), 20ng/ml
rmIL-23 (R&D Biosystems), and 20ng/ml rmIL-1β (Miltenyi Biotec). Cells were cultured
for 4 days and harvested for RNA, intracellular cytokine staining, and for flow cytometry.
Cytokine analysis (ELISA) and real time PCR
Cytokines in culture supernatants were collected on day 4 and determined by enzyme-linked
immunosorbent assay (ELISA) as previously described 10. On day 4 (unless otherwise
noted) post culture, RNA was extracted with RNeasy kit (Qiagen), reverse transcribed using
iscript cDNA synthesis kit (Bio-rad, CA), and was analyzed by quantitative RT-PCR with
vii7 Real-time PCR systems (Applied Biosystems) for the gene of interest. Primer/probe
mixtures were purchased from Applied Biosystems. The comparative threshold cycle
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tmethod and an internal control (GAPDH) were use for normalization of the target genes.
The list of primer and probes from Applied Biosystems: Cxcl3: Mm01701838_m1, Il3:
Mm00439631_m1, Csf2: Mm01290062_m1, Il1rn: Mm01337566_m1, Lrmp:
Mm00493168_m1, Gzmb: Mm00442834_m1, Tbx21: Mm00450960_m1, Il17a:
Mm00439618_m1, Il17f: Mm00521423_m1, Ifng: Mm01168134_m1, Ahr:
Mm00478932_m1, Il9: Mm00434305_m1, Il10: Mm00439614_m1, Maf: Mm02581355_s1,
Il22: Mm00444241_m1, Il23r: Mm00519943_m1, Rorc: Mm00441144_g1, Tgfb1:
Mm01178820_m1, Tgfb2: Mm00436955_m1, Tgfb3: Mm01307950_m1, GAPDH:
4352339E
TGF-β PCR array
TGF-β/BMP PCR array kit was purchased from Sabiosciences and cells were processed
using manufacturer’s protocol. Naïve CD4 T cells (CD44neg CD62L+ CD4+) were sorted
using BD Biosciences FACAria Cell sorter and cultured in vitro under TGF-β1/IL-6 or
TGF-β3/IL-6 conditions. After 24 hours, cells were harvested and total RNA was purified
using RNeasy mini kit (Qiagen, CA). RNA was converted to cDNA using manufacturer’s
cDNA sythesis kit, RT2 First Strand Kit (Sabiosciences, CA). SYBR Green qPCR Master
mix provided by the manufacturer was used and plated in pre-coated 96 well PCR array kit.
RT-PCR was performed using the vii7 real time PCR system (Applied Biosystems, CA).
Raw data was uploaded onto the manufacturer’s website and analyzed.
Histopathologic analysis
Mice were sacrificed 30 days after transfer and the CNS fixed in 10% neutral-buffered
formalin and processed routinely for paraffin embedment. Inflammatory foci (>10
mononuclear cells) were quantified in the meninges and parenchyma by a pathologist in a
double blind manner, such that disease status of the mice as well as the cell transfer groups
were not revealed.
Microarray analysis
Wt naïve T cells were sorted and activated for 4 days with plate bound anti-CD3, anti-CD28
alone, or with the indicated cytokines. RNA was purified using the RNeasy kit (Qiagen,
RD), amplified using the Ovation Biotin RNA Amplification and Labeling System (NuGEN,
CA). The cDNA (10µg) was fragmented, labeled, and hybridized to GeneChip Mouse
Genome 430 2.0 arrays (Affymetrix). The data was normalized using the GenePattern
software 48 with the Robust Multi Array (RMA) algorithm 49. Since the data was collected
in two batches (SOM), we use the COMBAT software to remove batch effects 50. For our
clustering analysis (Fig. 4a) we only considered probe sets that show at least two fold
change (up or down) compared with the no-cytokine (TH0) state in at least one of the
conditions (572 probe sets corresponding to 434 genes; when several repeats were available,
we take the average fold change over all repeats). We clustered the genes using average
linkage hierarchical agglomerative clustering.
To directly compare the gene expression profiles of TGF-β1/IL-6 and TGF-β3/IL-6 TH17
cells we considered genes that showed at least a 1.5 fold change (up or down) between these
two conditions. From the 233 genes that showed at least a 1.5 fold change (Supplementary
Table 1), we selected 23 representative genes based on their biological function for further
validation and principal component analysis (PCA). Similar results were obtained when
PCA was performed using all 233 genes that showed at least a 1.5 fold change or only the 23
representative genes (Fig. 4d and e).
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GraphPad Prism 4.0 was used for statistical analysis (linear regression with 95% confidence
interval, and unpaired, two-tailed Student’s t test). Differences were considered statistically
significant when p < 0.05. * denotes. *p<0.05, **p<0.01, ***p<0.001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. The induction of TGF-β3 in TH17 cells
(a) Mean clinical scores (disease incidence) in wild-type recipients 30 days after transfer of
naïve CD4+ T cells (5×106 cells) from 2D2 transgenic mice that were differentiated in vitro
with TGF-β1-IL-6-IL-23 or TGF-β1-IL-6. (b) Quantitative RT-PCR analysis of Tgfb3
mRNA in naïve CD4+ T cells differentiated for four day in vitro with TGF-β1-IL-6-IL-23 or
no cytokines. (c) Quantitative RT-PCR analysis of Tgfb3 mRNA in naïve CD4+ T cells from
wild-type (WT) or Il23r−/− mice differentiated in vitro with TGF-β1-IL-6-IL-23 or no
cytokines. (d) Flow cytometry analysis of TGF-β3-YFP expression in CD4+ T cells, CD8+
T cells, γδ T cells and B cells from the lymph nodes and spleen of TGF-β3crexRosa26yfp
mice. (e) Intracellular cytokine staining showing co-expression of TGF-β3-YFP with either
IL-17 or IFN-γ in naïve CD4+ T cells from MOG35–55+CFA immunized TGF-
β3crexRosa26yfp mice stimulated with PMA+ionomycin four days post in vitro culture with
or without IL-23. (f) Intracellular cytokine staining showing IL-17 and IFN-γ expression in
PMA+ionomycin ex-vivo stimulated splenocytes from MOG35–55-immunized TGF-
β3Cre+xRosaDTR and TGF-β3Cre-xRosaDTR littermate control (WT) mice treated with
diptheria toxin on day 4 post-immunization. (g) IL-17 expression in naïve TGF-β3fl/fl CD4+
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tT cells cultured in vitro with IL-1β-IL-6-IL-23 (TH17) or no cytokines (TH0) then
retrovirally transduced with Cre-GFP to delete TGF-β3. All data are a representative of
more than three independent experiments with similar results. Statistical significance of
*p<0.05, **p<0.01, or ***p<0.001 is indicated for the RT-PCR data. Error bars indicate
mean ± s.d.
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tFigure 2. TGF-β3-induced TH17 cells are highly pathogenic in inducing autoimmunity
(a) Intracellular cytokine staining showing IL-17 expression of PMA+ionomycin stimulated
naïve CD4+ T cells from C57BL/6 (wt) mice differentiated in vitro with TGF-β1-IL-6 or
TGF-β3-IL-6 for four days. (b) ELISA showing IL-17 production from supernatants of
naïve CD4+ T cells from C57BL/6 (wt) mice stimulated in vitro with TGF-β1, TGF-β3,
TGF-β1-IL-6, TGF-β3-IL-6 for four days. (c,d) Quantitative RT-PCR of Rorc, IL-17a,
IL-17f, IFNγ, Il23r and Il22 mRNA expression from wt naïve CD4+ T cells stimulated in
vitro with TGF-β1-IL-6, TGF-β3-IL-6 or no cytokines for four days. (e) Flow cytometry
analysis of IL-23R-GFP expression of naive CD4+ T cells from IL-23R-GFP knock-in mice
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tdifferentiated in vitro with TGF-β1-IL-6, TGF-β3-IL-6 or no cytokines for four days (f)
Mean clinical scores (disease incidence) in wild-type recipients 30 days after transfer of
naïve CD4+ T cells (5×106 cells) from 2D2 transgenic mice that were differentiated in vitro
with TGF-β1-IL-6 or TGF-β3-IL-6. Statistical analysis by linear regression curve was
performed and graphed including the 95% confidence band of the regression line
(***p<0.001) (g) Quantification of CNS lesions in the meninges and parenchyma from
recipient mice sacrificed on day 30 (**p<0.01). Data is pooled from three independent
experiments (n=6). (h) TGF-β signaling PCR array analysis of Smad 1, 3, 5 from wt naïve
CD4+ T cells differentiated with TGF-β1-IL-6 or TGF-β3-IL-6 for 24 hours. cDNA was
prepared and processed according to manufacturer’s instruction (Sabioscience, CA). The
graph illustrates the relative fold change in the Smads of TGF-β3-IL-6 condition compared
to TGF-β1-IL-6. The dotted line represents the normalized expression of TGF-β1-IL-6 set at
one for each of the Smads. The data is pooled from three independent replicates. (i) Flow
cytometry analysis showing p-smad1&5 or p-smad3 expression from wt naïve CD4+ T cells
stimulated with TGF-β1 or TGF-β3 for 30 minutes. Adoptive transfer data from (f) is a
representative of four independent experiments. All data are a representative of more than
three independent experiments, unless otherwise mentioned, with similar results. Statistical
significance of *p<0.05, **p<0.01, or ***p<0.001 is indicated for the RT-PCR data. Error
bars indicate mean ± s.d.
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tFigure 3. The pathogenicity of TGF-β3–IL-6 TH17 cells are highly comparable to IL-1β-IL-6-
IL-23 TH17 cells
(a) Flow cytometry analysis showing IL-17-GFP expression in naïve CD4+ T cells from the
IL-17-GFP knock-in mice differentiated in vitro with IL-1β-IL-6-IL-23, TGF-β3-IL-6, or no
cytokines for four days. (b) Quantitative RT-PCR analysis of Il23r mRNA expression from
naïve CD4+ T cells from wt mice differentiated in vitro with IL-1β-IL-6-IL-23, TGF-β3-
IL-6, or no cytokines for four days. (c) Mean clinical scores (disease incidence) in wild-type
recipients 30 days after transfer of naïve CD4+ T cells (5×106 cells) from 2D2 transgenic or
2D2xIL-23R−/− mice that were differentiated in vitro with IL-1β-IL-6-IL-23 or TGF-β3-
IL-6. Statistical analysis by linear regression curve was performed and graphed including the
95% confidence band of the regression line. (ns) denotes not significant. (d) Quantitative
RT-PCR showing Tgfb3 mRNA expression of CNS-infiltrating CD4+ T cells isolated from
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tMOG35–55+CFA+pertussis toxin (PT) immunized wt mice with either score 2–3 (peak of
disease) or score 0 (no disease). Figure represents data of twelve individual mice pooled
from three independent experiments. (e) Mean clinical scores (disease incidence) in wt mice
immunized with MOG35–55+CFA+PT with either isotype control or anti-TGF-β3
neutralizing antibody in the emulsion then monitored for 21 days. Statistical analysis by
linear regression curve was performed and graphed including the 95% confidence band of
the regression line. Adoptive transfer data from (c) is pooled data from three independent
experiments (n=8) and (e) is pooled data from two independent experiments (n=10).
Cumulative data on the number of animals used are shown in Table 1. All in vitro
experiments are a representative of at least three independent experiments unless specified
differently. Error bars indicate mean ± s.d. (**p<0.01). (ns) denotes not significant.
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tFigure 4. Identification of transcriptional signature for pathogenic TH17 cells
(a) A heat map of the microarray analysis showing differential expression of 434 genes that
were up- or down-regulated (>2 fold; compared with TH0 cells) from wt naïve CD4+ T cells
differentiated in vitro with IL-1β-IL-6, IL-1β-IL-6-IL-23, TGF-β1-IL-6, TGF-β1-IL-6-
IL-23, TGF-β3-IL-6, or TGF-b3-IL-6-IL-23 for 60 hours. (b) Bar graph representing
analysis of 23 genes selected from a pool of 233 targets that had greater than 1.5 fold
difference between TGF-β3-IL-6 and TGF-β1-IL-6 differentiated TH17 cells. Data is
represented as a fold change of TGF-β3-induced TH17 cells over TGF-β1-induced TH17
cells. Up-regulated genes denote a “pathogenic signature” from TGF-β3-induced TH17 cells
while down-regulated genes are “nonpathogenic signature” from TGF-β1-induced TH17
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tcells. (c) Quantitative RT-PCR analysis showing mRNA expression of several targets
highlighted in (b) from wt naïve CD4+ T cells differentiated in vitro with TGF-β1-IL-6 or
TGF-β3-IL-6 for four days. Error bars indicate mean ± s.d., *p<0.05, **p<0.01,
***p<0.001). Data is pooled from at least four independent experiments. (d,e) Principal
component analysis (PCA) of the 23 selected genes (d) or 233 genes (e) that were
differentially expressed and had greater than 1.5 fold difference between the TGF-β3-IL-6
and TGF-β1-IL-6 differentiated TH17 groups.
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tFigure 5. Exogenous TGF-β3 can overcome the absence of T-bet
(a) Intracellular cytokine staining showing IL-17A and IFN-γ expression in naïve CD4+ T
cells from 2D2 or 2D2 Tbx21−/− mice stimulated with PMA+ionomycin after in vitro
differentiation with TGF-β1-IL-6-IL-23 for four days. (b) Mean clinical scores (disease
incidence) in wild-type recipients 30 days after transfer of naïve CD4+ T cells (5×106 cells)
from 2D2 transgenic or 2D2 Tbx21−/− mice that were differentiated in vitro with TGF-β1-
IL-6-IL-23. Analysis by linear regression curve was performed and graphed including the
95% confidence band of the regression line. Data is pooled from two independent
experiments (n=7). (c) Quantitative RT-PCR analysis of Tgfb3 mRNA expression from
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tTbx21−/− or wt naïve CD4+ T cells differentiated in vitro with IL-1β-IL-6-IL-23, IL-6-IL-23
or no cytokines for four days (d) Quantitative RT-PCR of Tgfb3 mRNA expression of wt
CD4+ T cells differentiated in vitro with IL-1β-IL-6-IL-23, IL-6-IL-23 or no cytokines and
retrovirally over-expressed with T-bet-RV or empty-vector-RV (both Thy1.1 marker) for
four days. (e) Mean clinical scores (disease incidence) in wild-type recipients 30 days after
transfer of naïve CD4+ T cells from 2D2 Tbx21−/− mice (5×106 cells) that were
differentiated in vitro with TGF-β1-IL-6 or TGF-β3-IL-6. Analysis by linear regression
curve was performed and graphed including the 95% confidence band of the regression line.
Data is pooled from three independent experiments (n=11). (f) Quantification of CNS
lesions in the meninges and parenchyma from recipient mice sacrificed on day 30
(***p<0.001). Data was pooled from three independent experiments, n=4. (g) Intracellular
cytokine staining of IFNγ and IL-17 expression from naïve wt and Tbx21−/− CD4 T cells
differentiated in vitro with TGF-β1-IL-6, TGF-β3-IL-6, or no cytokines for four days. All in
vitro experiments are representative of at least three experiments with similar results.
Adoptive transfer experiments are pooled from two to three independent experiments and
cumulative data on the number of animals used are shown in Table 1.
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